PM-8003 is under clinical development by Biotheus and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PM-8003’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PM-8003 is under development for the treatment of advanced malignant solid tumors including renal cell carcinoma, hepatocellular carcinoma, esophageal carcinoma, non-small cell lung cancer and ovarian cancer. The therapeutic candidate is a tri-specific monoclonal antibody. It is administered through intravenous route.
Biotheus is a biotechnology company which discovers and develops cancer immunotherapies. It is investigating bispecific, trispecific and monoclonal antibody candidates including PM8001, PM8002, PM8003, PM1001, PM1003, PM1008, PM1009, PM1010 and PM1011 to treat cancer and improve the immune system’s natural ability to fight the disease. Biotheus is also evaluating its antibody-based pipeline programs in partnership with Adimab LLC, Alligator Bioscience AB, Genbase Biotechnology Co Ltd and TILT Biotherapeutics Ltd. It examines the mechanisms of Treg (regulatory T) cells and inborn immunity at its research and development labs in Jiangsu, China; and Sha Tin, Hong Kong. Biotheus is headquartered in Zhuhai, Guangdong, China.
For a complete picture of PM-8003’s drug-specific PTSR and LoA scores, buy the report here.